FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations

The FDA approved the use of Braftovi and Mektovi in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by the THxID BRAF Kit (bioMérieux), which was also approved.